Actinogen Medical Limited (ASX:ACW): How Brain Cortisol Research Shapes Its Alzheimer’s Trial

Aditi Sarkar

14 October 2026 08:14 PM AEDT

Actinogen Medical Limited (ASX:ACW): How Brain Cortisol Research Shapes Its Alzheimer’s Trial

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Actinogen’s investigational medicine Xanamem targets 11β-HSD1, an enzyme involved in local cortisol production.
The XanaMIA Phase 2b/3 trial evaluates Xanamem in people with mild to moderate Alzheimer’s disease.
On 23 September 2026, the company announced completion of the final participant visit.
FY26 research and development expenditure reached $19,027,365, reflecting clinical program activity.
At 30 June 2026, the company reported cash and cash equivalents of $16,734,937.

Actinogen Medical Limited (ASX:ACW) develops treatments for neurological and neuropsychiatric conditions associated with dysregulated brain cortisol. Its principal investigational medicine, Xanamem (emestedastat), is designed to inhibit the 11β-HSD1 enzyme. During 2026, the company concentrated on its XanaMIA Alzheimer’s disease study, regulatory discussions and managing resources for clinical development.

Why Brain Cortisol Is Central to Xanamem

Unlike treatments directed at all cortisol production in the body, Xanamem is intended to lower cortisol generated within tissues, including areas of the brain involved in memory and cognition. Actinogen Medical Limited (ASX:ACW) identifies the hippocampus and frontal cortex as relevant regions for this mechanism. The aim is to test whether controlling local cortisol can alter clinical outcomes, not to assume that reducing cortisol has already demonstrated a benefit in Alzheimer’s disease.

Xanamem remains an investigational therapy and is not approved for routine medical use. The mechanism provides a scientific rationale for research; any claim about clinical effectiveness must be established through trial results.

XanaMIA Trial Reaches a 2026 Milestone

The XanaMIA Phase 2b/3 study enrolled 247 participants with mild to moderate Alzheimer’s disease. The randomised trial compares once-daily Xanamem 10 mg against placebo, using the Clinical Dementia Rating–Sum of Boxes scale as its primary endpoint. Actinogen Medical Limited (ASX:ACW) reported on 23 September 2026 that the final participant visit had been completed, marking the end of scheduled assessments in the main trial.

In August 2026, the company stated that topline results were anticipated in November 2026. That timing was guidance rather than a reported outcome. The open-label extension, which began in March 2026, allows eligible trial participants to receive Xanamem and supports further collection of safety information.

FY26 Expenditure and Financial Resources

For the year ended 30 June 2026, Actinogen Medical Limited (ASX:ACW) reported a net loss after tax of $15,379,848 and research and development expenditure of $19,027,365. The company attributed substantial research spending to clinical trials. These figures describe the cost of developing its medicine rather than sales from an approved treatment.

Cash and cash equivalents were $16,734,937 at 30 June 2026. Actinogen also reported receipt of a $7.3 million research and development tax incentive rebate relating to the preceding financial year. Management said its available resources extended beyond the expected XanaMIA results to mid-2027, although funding requirements will depend on subsequent development decisions.

Regulatory Pathway and Clinical Uncertainty

Actinogen Medical Limited (ASX:ACW) stated in its August results announcement that it had reached a common understanding with US and European regulators about potential Alzheimer’s development pathways, including the design of another pivotal study planned to commence in 2027. Regulatory engagement does not itself constitute a marketing approval.

Clinical outcome uncertainty remains central. The trial must establish whether any observed effects are meaningful and reproducible, while further studies, regulatory assessments, manufacturing and financing may be required. The company’s plans also depend on the available evidence and its financial capacity.

Key Insights

Actinogen Medical Limited (ASX:ACW) entered the final stage of its 2026 XanaMIA assessments with a clearly defined target, an investigational oral medicine and a reported funding position. The September participant-visit milestone establishes progress in study execution, but efficacy, safety and any eventual regulatory pathway remain matters for clinical evidence and formal review.

FAQs

Q: What does Actinogen Medical develop?

A:It develops investigational treatments for conditions associated with dysregulated cortisol in the brain.

Q: What is Xanamem?

A:Xanamem is an investigational once-daily medicine designed to inhibit the 11β-HSD1 enzyme.

Q: What is the XanaMIA trial studying?

A:It evaluates Xanamem against placebo in people with mild to moderate Alzheimer’s disease.

Q: Did XanaMIA report final efficacy results in September 2026?

A:No. The company announced completion of the final participant visit, not final efficacy results.

Q: What was the company’s FY26 cash balance?

A:Cash and cash equivalents totalled $16,734,937 at 30 June 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.